Pfizer's portfolio includes 12 products with individual revenues exceeding $1 billion in 2011. Many of our leading prescription medicines are top-sellers in their categories, and are among the most widely recognized and well-tested treatments in the world.
Celebrex (celecoxib capsules), a prescription nonsteroidal anti-inflammatory, is a treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis, and in the U.S. and certain EU countries for the management of acute pain in adults. Celebrex is supported by continued educational and promotional efforts highlighting its efficacy and safety profile for appropriate patients.
For more information visit Pfizer Pharmaceutical Products
Enbrel (etanercept) is used to treat moderate to severe rheumatoid arthritis, moderately to severely active polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, adult chronic moderate to severe plaque psoriasis and ankylosing spondylitis, a type of arthritis affecting the spine. A biologic that can be self-injected, Enbrel was the first biologic approved for moderate-to-severe rheumatoid arthritis, and has more than a decade of continuous safety data in patients with rheumatoid arthritis.
For more information visit Pfizer Pharmaceutical Products
Lipitor (atorvastatin) is prescribed to treat elevated LDL-cholesterol levels in the blood. In 2011, it was the most widely used branded prescription treatment for lowering cholesterol and the best-selling prescription pharmaceutical product of any kind in the world. Lipitor is proven to reduce the risk of heart attack, stroke and other cardiovascular events in patients with certain cardiovascular risk factors or with heart disease. Despite losing exclusivity in many markets, including the U.S. in 2011, Lipitor continues to be one of Pfizer's most important products.
For more information visit Pfizer Pharmaceutical Products
Lyrica (pregabalin) is indicated for the management of fibromyalgia, neuropathic pain associated with diabetic peripheral neuropathy (diabetic nerve pain), post-herpetic neuralgia (pain after shingles) and as an adjunctive therapy for adults with partial onset seizures in the U.S., and for neuropathic pain, adjunctive treatment of epilepsy and general anxiety disorder in certain countries outside the U.S.
For more information visit Pfizer Pharmaceutical Products
Norvasc (amlodipine besylate), despite facing generic competition since 2007, remains the world's most prescribed brand name pharmaceutical for high blood pressure. Pfizer makes and distributes generic versions of Norvasc through the Established Products/Emerging Markets Business Unit and continues to make the branded version widely available.
For more information visit Pfizer Pharmaceutical Products
Prevnar 13/Prevenar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a 13-valent pneumococcal conjugate vaccine. First introduced in 2009, it is now the world's top-selling pneumococcal vaccine, and is approved for infants and young children in more than 110 countries. It was recently approved in the U.S. and Europe and more than 10 other countries for use in adults 50 years and older.
For more information visit Pfizer Pharmaceutical Products
Pristiq (desvenlafaxine) is used to treat major depressive disorder in adults, and is believed to work on two chemicals in the brain, serotonin and norepinephrine. In contrast to many other antidepressants that must be started at a low dose and titrated up to a therapeutic dose, Pristiq patients can start at a dose proven to relieve depression symptoms: 50 mg, one pill, once a day. In addition, Pristiq does not undergo CYP2D6 metabolism in the liver, thereby reducing the risks of pharmacokinetic drug-drug interaction with other medications that do need to be metabolized through this important enzyme system.
For more information visit Pfizer Pharmaceutical Products
Sutent (sunitinib malate) is used by oncologists to treat advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors after disease progression on, or intolerance to, imatinib mesylate, and advanced pancreatic neuroendocrine tumors. The third indication was approved in late 2010 in the EU and in 2011 in the U.S. Sutent's efficacy in first-line mRCC includes two-year survival data, the first time that overall survival of two years has been seen in the treatment of advanced kidney cancer.
For more information visit Pfizer Pharmaceutical Products
Viagra (sildenafil citrate) is the No. 1 prescribed treatment for erectile dysfunction (ED) in the world and one of the world's most recognized pharmaceutical brands. Introduced in 1998, Viagra is backed by more than 13 years of patient experience, and has been shown to effectively treat ED in men who have concomitant health issues such as hypertension, depression and diabetes.
For more information visit Pfizer Pharmaceutical Products
Zyvox (linezolid) is the world's best-selling branded agent for the treatment of certain serious complicated skin and nosocomial pneumonia infections caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Zyvox works against MRSA by a unique mechanism of action, minimizing the potential for cross-resistance. Available in both oral and intravenous forms, and approved for adults and children, Zyvox offers doctors considerable flexibility in the transition of patients from hospital settings to home or other convalescent care.
For more information visit Pfizer Pharmaceutical Products
Eliquis (apixaban), which is being developed and commercialized with our alliance partner Bristol Myers-Squibb, was approved in Europe in May 2011 for the prevention of venous thromboembolism in patients who have undergone elective hip or knee replacement. Filings for stroke prevention in patients with atrial fibrillation have been accepted in Europe and the U.S. The companies also have submitted that indication for review in Japan.
Inlyta (axitinib) was approved in January 2012 in the U.S. for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
Oxecta (oxycodone HCL, USP), Tablets CII was approved in the U.S. in June 2011 for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta is the first immediate-release oxycodone medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. Pfizer is licensing the technology in Oxecta from Acura Pharmaceuticals.
Vyndaqel (tafamidis) was approved in the European Union in November 2011 for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with Stage 1 symptomatic polyneuropathy. This approval represents a major advance as Vyndaqel is the first and only medicine to delay neurological impairment for patients suffering from this rare, progressive and nearly always fatal neurogenerative disease, estimated to affect 8,000 people worldwide.
Xalkori (crizotinib) was approved in the U.S. in August 2011 as the first and only therapy for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer.
Xiapex (collagenase clostridium histolyticum) was approved in Europe in February 2011 as a new nonsurgical treatment option for Dupuytren's contracture—a thickening and contracture of tissue beneath the palm and fingers, in adult patients with a palpable cord. Dupuytren's disease is a slowly progressive connective tissue disorder that can cause the affected finger to bend into the palm of the hand.
